Austin Argentieri | Measuring Ageing | Milan Longevity Summit 2026

**Austin Argentieri, Researcher, Broad Institute* *Developing robust aging biomarkers via proteomics and genomics: perspectives from large human studies* -- How can large-scale human studies help us measure—and ultimately slow—the ageing process? In this session from Measuring Ageing: Biomarkers, Clocks, and Predictive Tools at the Milan Longevity Summit 2026, Austin Argentieri explores how advances in proteomics, genomics, and population-scale research are accelerating the discovery of robust biomarkers of biological ageing. By analysing vast datasets that combine genetic, molecular, and clinical information from thousands of individuals, researchers are identifying biological signatures that can predict disease risk, monitor the ageing process, and evaluate the effectiveness of interventions. The discussion highlights how these next-generation biomarkers are laying the foundation for precision longevity medicine and more personalised approaches to healthy ageing. Austin Argentieri is a researcher at the Broad Institute of MIT and Harvard, where he focuses on the development of biomarkers of biological ageing using large-scale genomic and proteomic datasets. His work combines computational biology, epidemiology, and multi-omics approaches to better understand the mechanisms of ageing and to develop predictive tools that can improve disease prevention and precision healthcare. The Milan Longevity Summit brings together global leaders across science, medicine, policy, business, technology and society to rethink the future of health through a One Health perspective—recognising that the wellbeing of people, planet and economies is deeply interconnected. *Learn more about the Milan Longevity Summit:* https://www.milanlongevitysummit.org/it/speakers26/austin-argentieri #MilanLongevitySummit #Longevity #OneHealth #AustinArgentieri #Proteomics #Genomics #Biomarkers #PrecisionMedicine #HealthyAgeing #Healthspan